PegBio (HKG:2565) reported a loss attributable to equity shareholders of the company of 93.62 million yuan for the first half of 2025, compared with a loss of 155.37 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.

Shares of the biotechnology firm were up over 1% in Wednesday late-morning trade.

Loss per share came in at 0.25 yuan, compared with 0.42 yuan in the prior-year period.

Other net income was 178,000 yuan, compared with 4.05 million yuan a year earlier.

The firm said it has no products approved for commercial sale and has not generated any revenue from product sales.